The lung is a common site of metastatic disease, which may be the only measurable malignancy in some patients. Unfortunately, because of the invasiveness of previous techniques and the fragility of these target organs, many attempts at regional lung therapies have not become that popular. Accordingly, a method for thoracoscopic vascular control to enable permeation of the lung with agents was developed and termed suffusion to distinguish it from earlier methods. This article describes the preclinical work supporting lung suffusion and our early human experience.